My Cart (0 )
-
Previous
HSPC/Chol/DSPE-mPEG2000/DSPE-mPEG2000-maleimide/MPL (49/45/4/1/1, mol/mol) Liposomes
Price range: $750.00 through $2,380.00
-
Next
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Price range: $595.00 through $3,195.00
Adavosertib Liposomes, Formulation WD4
Price range: $995.00 through $4,995.00
PEGylated liposomes containing Wee-1 kinase inhibitor adavosertib (MK1775; AZD1775), remote loaded by an ammonium sulfate gradient. The lipid composition of the liposomes is the same as Doxil. Sterile filtered and supplied ready for use in preclinical studies in rodents or in vitro. Adavosertib is a potent, ATP-competitive Wee-1 kinase inhibitor, which hinders the G2 DNA damage response checkpoint and is reported to enhance cytotoxic effects of several compounds including 5-FU and NSC 613327. For preclinical research use only.
We synthesize custom liposomes like this. Contact us today to request a custom formulation.
Available Options:
Specifications
Product Data:
Figure 1 (Thumbnail). Enhancement of solubility for adavosertib is shown in the representative images. Adavosertib is insoluble in aqueous media at the specified concentration (1 mg/mL). Matched concentration of adavosertib liposomes is shown after loading by ammonium sulfate gradient.
Figure 2. DLS analysis of Adavosertib Liposomes, Formulation WD4 (batch 10003). The average size and PDI of triplicate measurements are annotated on the representative snapshot from DLS data acquisition screen. The data are representative of a typical batch.
Details
Adavosertib is a potent, ATP-competitive Wee-1 kinase inhibitor, which hinders the G2 DNA damage response checkpoint [1, 2]. Adavosertib is reported to enhance cytotoxic effects of several compounds including 5-FU and NSC 613327 [2, 3]. Adavosertib is insoluble in water. Formulation WD4 is a liposome pre-formulated version of adavosertib which is supplied at 1.0 mg/mL adavosertib in preformed liposomes and is ready to use for in vitro or in vivo preclinical studies. Adavosertib is remote loaded by an ammonium sulfate gradient. The liposomes are PEGylated to enhance circulation time and reduce RES uptake in vivo. This product could be used alone or as a potentiating agent in combination with other bioactive compounds, depending on the mechanism of action of the companion agent. For preclinical research use only.
|
|
|
|
DLL-0005 |
|
|
PEGylated liposomes loaded with Adavosertib by ammonium sulfate gradient |
|
| Formulation No. | WD4 |
| Lipid Composition | HSPC/Chol/DSPE-mPEG2000 (56.2/38.5/5.3, mol/mol) |
| Concentration Total Lipid | 27.2 mM |
| Concentration Adavosertib | 1.0 mg/mL |
| Hydration Solution | 250 mM Ammonium Sulfate, pH 5.5 |
| External Solution | Normal Saline (154 mM NaCl, pH 5.5) |
| Liposome Avg. Size | 70-120 nm |
Bioactive Compound Details
|
|
| Encapsulated Compound | Adavosertib |
| Alias(es) | AZD-1775; MK-1775 |
| CAS No. | 955365-80-7 |
| Target | Wee1 kinase |
| Signaling Pathway | DNA damage response |
| CAS No. | AZD-1775; MK-1775 |
| Description | Adavosertib is a potent Wee1 inhibitor with an IC50 of 5.2 nM. |
Custom Orders
We synthesize custom liposomes like this. Contact us today to request a custom formulation.
Additional Information
Additional Information
| Liquid, suspension | |
| 2 °C to 8 °C (do not freeze) | |
| Shelf Life* | 6 months |
| HSPC: L-α-phosphatidylcholine, hydrogenated (Soy); Chol : Cholesterol; DSPE-mPEG2000: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] |
*When maintained under the specified storage conditions.